Research progress in treatment of myelodysplastic syndrome with allogeneic hematopoietic stem cell transplantation

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective method for treatment of myelodysplastic syndrome (MDS) and is the only method that may make MDS to be curable. With the advancement of hematopoietic stem cell transplantation (HSCT), more and more patients with MDS have the opportunity to receive allo-HSCT. Identifying the indications for allo-HSCT in treatment of MDS, selecting the appropriate timing of allo-HSCT, pre-transplant therapy, donors, stem cell sources and transplantation conditioning are critical for the treatment outcome of patients with MDS. Therefore, this article summarizes the research progress in these aspects mentioned above. Key words: Hematopoietic stem cell transplantation; Myelodysplastic syndrome; Graft vs host disease; Peripheral blood stem cell transplantation